Moderna’s stock closed down 5.6% at $39.77, bringing the stock to its lowest point of the year. Sanofi’s stock dropped 3.4% ...

Treatment with ACI-7104.056 induced an increase in anti-a-syn antibodies on average 16-fold higher than the placebo background level after three immunisations. CEO of AC Immune, Dr. Andrea Pfeifer, ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland ...

Sanofi in 2023. Amgen obtained a patent on ... to the US Supreme Court), tends to engage judges with a technical background. Of course, each of the US Supreme Court justices hires law clerks ...

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that the Company has received communication from its Registrar ...

Sanofi’s BTK in­hibitor rilz­abru­ti­nib helped 23% of adults with a rare au­toim­mune blood dis­or­der achieve tar­get platelet counts in a Phase 3 tri­al, com­pared to … ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with flagship products like Doliprane and Allegra, has been a reliable ...

"Peace with nature" was the theme of the 16th Conference of Parties to the Convention on Biological Diversity (COP16) that has drawn about 23 000 delegates from around the world to the South American ...

For elderly people and those who already have chronic background diseases with weakened immunity, facing influenza can be self-threatening. On October 9, Sanofi and Vietnam Vaccine JSC (VNVC), the ...